$Mitoxantrone and high-dose ara-C in refractory malignancies: A phase I trial$

Mitoxantrone and high-dose ara-C in refractory malignancies: A phase I trial

On the basis of in vitro studies demonstrating marked synergy between mitoxantrone and high‐dose cytosine arabinoside (ara‐C) (HiDAC) against L5178Y murine leukemia and clinical studies showing usefulness of the combination in patients with refractory acute myeloid leukemia, a phase I study was init...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical and pediatric oncology 1989, Vol.17 (2), p.159-163
Hauptverfasser:	Smith, William J., Muss, Hyman B., Capizzi, Robert L., White, Douglas R., Richards II, Frederick, Jackson, Don V., Powell, Bayard L., Zekan, Patricia J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bone Marrow - drug effects Chemotherapy Cytarabine - administration & dosage Cytarabine - therapeutic use Drug Evaluation Humans in vitro cytotoxicity Medical sciences Middle Aged Mitoxantrone - administration & dosage Mitoxantrone - therapeutic use myelosuppression Neoplasms - drug therapy Pharmacology. Drug treatments synergy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!